Expression and clinical significance of peptidylarginine deiminase 4 in non-small cell lung cancer

Abstract

Objective To investigate the expression and clinical significance of peptidylarginine deiminase 4 (PADI4) in non-small cell lung cancer (NSCLC) tissues. Methods The expressions of PADI4 mRNA and protein in NSCLC tissues and para-carcinoma tissues were detected by quantitative real-time polymerase chain reaction and immunohistochemistry, respectively.The correlations between PADI4 and NSCLC clinicopathological features and prognosis were also investigated. Results The expressions of PADI4 mRNA and protein were higher in NSCLC tissues than those in paired normal lung tissues (t=-80.384, χ2=27.66, all P<0.001). Furthermore, the expression of PADI4 was associated with TNM stage (χ2=22.225, P<0.05). The survival analysis showed that the survival time of patients in PADI4 high-expression group was lower than that in PADI4 low-expression group (P<0.001), indicating the poor prognosis of patients with PADI4 high-expression.The result of Cox multivariate regression analysis showed that PADI4 expression was an independent risk factor for the prognosis of NSCLC patients (P<0.05). Conclusions PADI4 is over-expressed in NSCLC tissues, and PADI4 expression is associated with TNM stage.PADI4 expression will be an independent risk factor for the prognosis of NSCLC patients. Key words: Peptidylarginine deiminase 4; Non-small cell lung cancer; Clinicopathological features; Prognosis